Antiplatelet medications


00:00 / 00:00



Antiplatelet medications

Hematological system


Anticoagulants: Heparin

Anticoagulants: Warfarin

Anticoagulants: Direct factor inhibitors

Antiplatelets and thrombolytics

Antiplatelet medications


Hematopoietic medications

Hematopoietic medications

Cancer medications

Ribonucleotide reductase inhibitors

Topoisomerase inhibitors

Platinum containing medications

Anti-tumor antibiotics

Microtubule inhibitors

DNA alkylating medications

Monoclonal antibodies

Antimetabolites for cancer treatment


Antiplatelet medications


0 / 15 complete


Antiplatelet medications

of complete

External References

First Aid








Abciximab p. 120

Glycoprotein IIb/IIIa inhibitors p. 445

thrombogenesis and p. 419

Antiplatelet antibodies p. 721

abciximab as p. 120



Sean Watts, MD

Elizabeth Nixon-Shapiro, MSMI, CMI

Sam Gillespie, BSc

Robyn Hughes, MScBMC

Antiplatelet medications prevent blood clot formation during hemostasis, where hemo means blood, and stasis means to halt or stop.

Hemostasis is divided into primary hemostasis, where circulating cell fragments called platelets form a plug at the site of an injured blood vessel, and secondary hemostasis, which involves multiple coagulation factors working together to form a fibrin mesh to stabilize the platelet plug.

Antiplatelet medications inhibit the steps of primary hemostasis to prevent the platelet plug from forming.

Primary hemostasis can be further divided into five steps: endothelial injury, exposure, adhesion, activation, and aggregation.

Endothelial injury is when the innermost layer of the artery, called the endothelium, gets damaged.

The second step is exposure, where the damaged endothelium exposes the underlying collagen.

The underlying collagen and endothelial cells then release a protein called Von Willebrand's factor, or vWF, that binds to this collagen.

The third step is adhesion where circulating platelets bind to the vWF via a surface protein called GPIB. The fourth step is activation, where platelets become active after binding to vWF.

First, the platelet changes shape and its membrane forms tentacle-like arms allowing it to grab onto other platelets.

Second, platelets release more vWF, as well as serotonin, a tiny molecule that attracts more platelets to the area.

Third, the platelets also release adenosine diphosphate or ADP, and thromboxane A2, or TXA2. These two molecules can activate other platelets that haven’t bound to vWF.


  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Nomograms" D. Nicoll , C. Mark Lu, S.J. McPhee (Eds.), Guide to Diagnostic Tests, 7e. McGraw-Hill (2017)
  5. "Overview of hemostasis" J.C. Aster, H. Bunn (Eds.), Pathophysiology of Blood Disorders, 2e. McGraw-Hill. (2016)
  6. "Not all (N)SAID and done: Effects of nonsteroidal anti‐inflammatory drugs and paracetamol intake on platelets" Research and Practice in Thrombosis and Haemostasis (2019)
  7. "Assessment of platelet function in patients receiving tirofiban early after primary coronary intervention" Interventional Medicine and Applied Science (2016)
  8. "The first‐generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue" Andrology (2019)

Copyright © 2023 Elsevier, except certain content provided by third parties

Cookies are used by this site.

USMLE® is a joint program of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). COMLEX-USA® is a registered trademark of The National Board of Osteopathic Medical Examiners, Inc. NCLEX-RN® is a registered trademark of the National Council of State Boards of Nursing, Inc. Test names and other trademarks are the property of the respective trademark holders. None of the trademark holders are endorsed by nor affiliated with Osmosis or this website.